This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
After Plunging -15.27% in 4 Weeks, Here's Why the Trend Might Reverse for Profound Medical (PROF)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Profound Medical (PROF) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zoetis (ZTS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recent Price Trend in Profound Medical (PROF) is Your Friend, Here's Why
by Zacks Equity Research
Profound Medical (PROF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Profound Medical (PROF) Q2 Earnings Expected to Decline
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profound Medical (PROF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 11.11% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 27th
by Zacks Equity Research
FRPT, PING, and PROF have been added to the Zacks Rank #5 (Strong Sell) List on April 27, 2022
Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -11.54% and -36.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROFOUND MEDICL (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -34.62% and 15.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PROFOUND MEDICL (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate PROFOUND MEDICL (PROF) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROFOUND MEDICL (PROF) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -40.74% and -4.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
PROFOUND MEDICL (PROF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
PROFOUND MEDICL (PROF) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.